ProShares Short Real Estate REK 深 滬
等待開盤 11-26 09:30:00 美东时间
17.0357
-0.141
-0.82%
華盛通- 最 高17.13
- 今 開17.13
- 成交量 3130股
- 最 低 16.98
- 昨 收 17.1769
- 總市值 1149.74万
- 52周最高 19.3145
- 市盈率 靜 --
- 換手率 0.46%
- 52周最低 15.8091
- 委 比 0.00%
- 總股本 67.49万
- 歷史最高 43.9289
- 量 比 0.44
- 振 幅 0.87%
- 歷史最低 13.3338
- 每 手 1
- 風險率 0.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多REKOR SYSTEMS ANNOUNCES PLAN TO ENTER THE GLOBAL DEEPFAKE DETECTION MARKET
Rekor Systems subsidiary Rekor Labs is developing advanced technology to detect synthetic media, targeting five key sectors: news, social media, government, enterprise, and entertainment. With a projected $30 billion market potential, the launch is expected in 2026, following successful proof of concept and alpha testing. The company has hired Moelis & Company as their financial advisor. Rekor Systems subsidiary Rekor Labs is developing advanced...
10-23 11:00
外资支付再下一城！易联支付更名“派安盈支付”
拥有二十年历史的“易联支付”之名，就此彻底成为历史。 近日，国家企业信用信息公示系统显示，易联支付有限公司已正式更名为派安盈支付（广东）有限公司（下称“派安盈支...
10-23 09:08
迪拜免税店今年以来销售屡破纪录 甜食和奢侈品表现亮眼
今年前七个月，DDF的销售额总计13亿美元，较去年同期增长5.86%。同时，今年前七个月中有五个月创下销售记录。 尽管地区冲突导致中东货运和客运减少，但迪拜在客...
08-05 15:06
Vertex reiterates $11.85B–$12B 2025 revenue guidance while boosting JOURNAVX commercial investment
Earnings Call Insights: Vertex Pharmaceuticals (VRTX) Q2 2025 Management View CEO Reshma Kewalramani highlighted "very strong performance across the board, growing and diversifying revenue with multip...
08-05 08:14
Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will release earnings results...
08-05 01:48
Vertex Pharma's ALYFTREK Approved By Health Canada For Cystic Fibrosis Treatment In Children And Adults With Responsive CFTR Mutations
- In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and superior in reducing sweat chloride compared to TRIKAFTA -- Approximately 3,800 people in Canada are now eligible for ALYFTREK,
07-23 00:58
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the di...
07-09 20:30
The European Commission Approves Vertex Pharmaceuticals' Alyftrek (Deutivacaftor/Tezacaftor/Vanzacaftor) For Cystic Fibrosis Patients Ages 6 Years And Older Who Have At Least One Non-class I Mutation In The Cystic Fibrosis Transmembrane Conductance Regulator Gene
ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR gene, making it the broadest label for this medicine in the
07-01 19:54
Is Airbnb Behind The Housing Crisis? Data Says No, But City Restrictions Can Still Affect Its Bottom Line
Short-term rental platform Airbnb (NASDAQ:ABNB) is keeping Wall Street flabberg...
2023-08-11 04:15
美国房地产玩砸了？这只ETF却嗨了，今年大涨80%
美联储持续加息之际，美国房贷利率也在持续狂飙，火热的美国楼市也蒙上一层阴影；看空房地产相关ETF成最大赢家，最高涨幅达80%，此外还有这些REITs值得关注>>
2022-09-23 22:30
